Both STP705 and STP707 are made of two siRNA oligonucleotides that hit transforming growth factor beta 1 (TGF-β1) and cyclooxygenase 2 (COX-2) mRNA, gatekeeper targets for oncology and fibrosis.

In its two lead cancer assets, STP705 and STP707, Sirnaomics is using the technology to deliver two siRNA oligonucleotides to knock down TGF-β1 and COX-2 gene expression. TGF-β1 and COX-2 are ...

The success of this methodology depends on choosing the proper target sequence within the gene of interest and proper design of the siRNA oliginucleotides. PAGE purification of your oligonucleotides ...

The category of genetic medicine for cardiovascular disease based on siRNA and antisense oligonucleotides is gathering momentum, with a series of new medicines on, or nearing, the market.

Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: Oligonucleotide Synthesis ...

Therapeutic oligonucleotides act on different stages of pathological gene expression. Standard schematic of oligonucleotide activities in pathogenesis disease progression. Decoys bind to transcription ...

Oligonucleotide API MarketThe global oligonucleotide API market is poised to grow from USD 2.81 billion in 2024 to USD 4.84 billion by 2034, expanding at a CAGR of 5.60%. The increasing need for ...

Advanced Cell Diagnostics™, a Bio-Techne brand, provide research tools that alleviate the challenges of traditional techniques and have recently launched their miRNAscope™ Assay to detect antisense ...

With experience in diverse therapeutic modalities such as small molecules, antisense RNAi oligonucleotides, monoclonal antibodies, vaccines, proteins, and peptides. The Hepatitis B - Global ...